Murray L. Aitken, SVP of IQVIA speaks about the requirements of small biopharma clinical development at the SCOPE 2023 conference in Orlando, FL.
In an interview at the 2023 SCOPE conference with ACT editor, Andy Studna, Murray L. Aitken, SVP of IQVIA discusses the requirements of small biopharma clinical development.
Three Must-Dos for Tracking Research and Development of Monoclonal Antibodies
November 2nd 2023There is an expanding array of potential antibody-based treatment options, such as bispecific or multispecific antibodies, that show promise in addressing conditions such as cancer, engineered antibody fragments, or even antibody-drug conjugates.